मूलभूत आँकड़े
| LEI | 549300G63SSKC2EGLN41 |
| CIK | 1369290 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Myomo, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, |
|
| August 11, 2025 |
Exhibit 99.1 Myomo Reports Second Quarter 2025 Financial and Operating Results Revenue of $9.7 million 816 patients added to the MyoPro pipeline Updates 2025 revenue guidance Conference call begins today at 4:30pm Eastern time BURLINGTON, Mass. (August 11, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality fo |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| June 18, 2025 |
Exhibit 99.1 Myomo Provides Highlights of Today’s Investor & Analyst Day Event Senior executives to provide an in-depth review of the Company’s business model and discuss long-range aspirational financial metrics BURLINGTON, Mass. (June 18, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those sufferin |
|
| June 18, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 23, 2025 |
Exhibit 1.01 Conflict Minerals Report of Myomo, Inc. For the Year Ended December 31, 2024 Introduction This is the Conflict Minerals Report (the “CMR”) of Myomo, Inc. (the “Company,” “we” or “us” or “our”) for the reporting period from January 1, 2024 to December 31, 2024 in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The Rule req |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Myomo, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-38109 47-0944526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 45 Blue Sky Dr., Suite 101, Burlington, Massachusetts 01803 (Address of principal e |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Empl |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, |
|
| May 7, 2025 |
Exhibit 99.1 Myomo Reports First Quarter 2025 Financial and Operating Results Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time BURLINGTON, Mass. (May 7, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medica |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 25, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| April 10, 2025 |
Myomo Announces Upcoming Changes to its Board of Directors Exhibit 99.1 Myomo Announces Upcoming Changes to its Board of Directors BURLINGTON, Mass. (April 10, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that directors Amy Knapp and Yitzchak Jacobovitz have informed the b |
|
| April 10, 2025 |
Letter from Marcum LLP, dated April 9, 2025. Exhibit 16.1 April 9, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Myomo, Inc. under Item 4.01 of its Form 8-K dated April 4, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Myomo, Inc. contained therein. Very truly yo |
|
| March 10, 2025 |
Employment Agreement dated December 13, 2023 by and between the Company and Paul R Gudonis Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is between Myomo, Inc. (“Myomo” or the “Company”), a Delaware corporation with offices at 137 Portland St., 4th Floor, Boston, MA 02114, and Paul R. Gudonis, an individual (“Executive”) residing at 56 Masconomo St., Manchester, MA 01944, is made as of the date of the last signature on the signature pages hereto and upon |
|
| March 10, 2025 |
Exhibit 21.1 Myomo, Inc. List of Subsidiaries Subsidiary Legal Name Employer ID Number % Owned State/Country Incorporated Myomo Europe GmbH NA 100% Germany |
|
| March 10, 2025 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Myomo, Inc. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per |
|
| March 10, 2025 |
Exhibit 97.1 Myomo, Inc. COMPENSATION RECOVERY POLICY Adopted as of September 13, 2023 Myomo, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and former Executive Officers |
|
| March 10, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| March 10, 2025 |
Exhibit 10.10 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (the “Amendment”) is made as of February 21, 2024, and amends the Employment Agreement dated April 22, 2021 between Myomo, a Delaware corporation (the “Company”), and Micah Mitchell (the “Executive”) (such Agreement, the “Employment Agreement”). NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, a |
|
| March 10, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 10, 2025 As filed with the U.S. Securities and Exchange Commission on March 10, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MYOMO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-0944526 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Emp |
|
| March 10, 2025 |
m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 10, 2025 |
Exhibit 19.1 MYOMO, INC. AMENDED AND RESTATED Insider Trading POLICY Myomo, Inc. (the “Company”) has adopted the following policy and procedures for securities trading by Company directors and employees (our “Insider Trading Policy”). Our Insider Trading Policy is intended to prevent the misuse of material nonpublic information, insider trading in securities, and the severe consequences associated |
|
| March 10, 2025 |
Exhibit 99.1 Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million Generated first-ever positive quarterly cash flow from operations Received a record 233 MyoPro® authorizations and orders with 657 additions to the pipeline Introduces 2025 revenue guidance of $50 million to $53 million Conference call being held today at 4:30pm Eastern time BURLINGTON, Mass. (March 10, 2 |
|
| February 20, 2025 |
Exhibit 10.1 FIRST Amendment to Loan and security agreement This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 18th day of February, 2025 by and between Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”) and MYOMO, INC., a Delaware corporation (“Borrower”), whose address is 137 Portland St., 4th Floor, Boston, MA 02114. Recitals |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| February 4, 2025 |
EX-99.A BD-DIR-RESOL 2 exAmyo14-02-2024.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salagon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Direct |
|
| December 5, 2024 |
3,000,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281311 PROSPECTUS SUPPLEMENT (to Prospectus dated August 28, 2024) 3,000,000 Shares of Common Stock We are offering 3,000,000 shares of our common stock by this prospectus supplement and the accompanying prospectus, at a public offering price of $5.00 per share. Our common stock is listed on NYSE American under the symbol “MYO |
|
| December 5, 2024 |
Exhibit 1.1 MYOMO, INC. 3,000,000 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement December 4, 2024 CRAIG-HALLUM CAPITAL GROUP LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Myomo, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Craig-Hallum Capital Group LLC, in its capacity as underwriter (the “Underw |
|
| December 5, 2024 |
MYOMO, INC. PRICES $15.0 MILLION PUBLIC OFFERING OF COMMON STOCK Exhibit 99.2 MYOMO, INC. PRICES $15.0 MILLION PUBLIC OFFERING OF COMMON STOCK BOSTON, December 5, 2024 – Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has priced an underwritten public offering of 3,000,000 shares of its common stoc |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 Myomo, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38109 47-0944526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 5, 2024 |
MYOMO, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 MYOMO, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK BOSTON, December 4, 2024 – Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it intends to offer and sell shares of its common stock in an underwritten public offe |
|
| December 4, 2024 |
Subject to Completion, dated December 4, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281311 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| November 6, 2024 |
Exhibit 99.1 Myomo Reports Record Third Quarter Financial and Operating Results $9.2 million in revenue, raises full-year revenue guidance 225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end 645 additions to the pipeline result in 1,263 patients in the pipeline as of September 30, 2024 BOSTON (November 6, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Compa |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MY |
|
| October 18, 2024 |
MYO / Myomo, Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindmyo13ga6sep20.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 6) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| October 18, 2024 |
EX-99.A BD-DIR-RESOL 2 exAmyo14-02-2024.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salagon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Direct |
|
| August 26, 2024 |
As filed with the Securities and Exchange Commission on August 26, 2024 Table of Contents As filed with the Securities and Exchange Commission on August 26, 2024 Registration No. |
|
| August 26, 2024 |
Myomo, Inc. 137 Portland St., 4th Floor Boston, MA 02114 Myomo, Inc. 137 Portland St., 4th Floor Boston, MA 02114 VIA EDGAR August 26, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Myomo, Inc. Acceleration Request for Registration Statement on Form S-3 Filed August 6, 2024, as amended on August 26, 2024 File No. 333-281311 Ladies and Gentlemen: Pursuant to Rule 461 under the Se |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| August 13, 2024 |
Lease Agreement, dated August 9, 2024, by and between the Registrant and NDB Property Owner 1. L.P. Exhibit 10.1 BLUE SKY CENTER OFFICE LEASE NDB PROPERTY OWNER 1, L.P. (AS LANDLORD) AND MYOMO, INC. (AS TENANT) FOR PREMISES AT 45 BLUE SKY DRIVE BURLINGTON, MASSACHUSETTS TABLE OF CONTENTS TABLE OF CONTENTS i ARTICLE 1 REFERENCE DATA 1 1.1 Subject Referred To 1 1.2 Exhibits 4 ARTICLE 2 PREMISES AND TERM 5 2.1 Premises 5 2.2 TERM 6 2.3 Extension Option 6 ARTICLE 3 IMPROVEMENTS 9 3.1 Performance of |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| August 6, 2024 |
Exhibit 99.1 Myomo Reports Second Quarter 2024 Financial Results Record revenue of $7.5 million Record 213 MyoPro® authorizations and orders Record 550 additions to the pipeline, with 1,179 patients in the pipeline at quarter-end BOSTON (August 6, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those s |
|
| August 6, 2024 |
As filed with the Securities and Exchange Commission on August 6, 2024 Table of Contents As filed with the Securities and Exchange Commission on August 6, 2024 Registration No. |
|
| August 6, 2024 |
As filed with the U.S. Securities and Exchange Commission on August 6, 2024 As filed with the U.S. Securities and Exchange Commission on August 6, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MYOMO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-0944526 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Emp |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, |
|
| August 6, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Myomo, Inc. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per |
|
| August 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Myomo, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Car |
|
| July 15, 2024 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date between SILICON VALLEY BANK, a division of First-Citizens Bank & Trust Company (“Bank”), and MYOMO, INC., a Delaware corporation (“Borrower”). The parties agree as follows: 1 LOAN AND TERMS OF PAYMENT 1.1 Revolving Line. (a) Availability. Subject to the terms and conditi |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| July 11, 2024 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. |
|
| July 11, 2024 |
MYO / Myomo, Inc. / Rosalind Advisors, Inc. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 5) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) June 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| July 11, 2024 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. |
|
| July 11, 2024 |
MYO / Myomo, Inc. / Rosalind Advisors, Inc. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 5) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) June 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| July 8, 2024 |
Exhibit 99.1 Myomo Reports Preliminary Second Quarter 2024 Revenues and Operating Metrics Expects record quarterly revenues of $7.2 million to $7.4 million, an increase of 92% to 97% sequentially Generates record pipeline additions, and authorizations and orders BOSTON (July 8, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers incr |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| June 4, 2024 |
MYO / Myomo, Inc. / Triple Gate Partners, LP - AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Myomo, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 62857J102 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| May 30, 2024 |
Exhibit 1.01 Conflict Minerals Report of Myomo, Inc. For the Year Ended December 31, 2023 Introduction This is the Conflict Minerals Report (the “CMR”) of Myomo, Inc. (the “Company,” “we” or “us” or “our”) for the reporting period from January 1, 2023 to December 31, 2023 in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The Rule req |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Myomo, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-38109 47-0944526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 137 Portland St., 4th Floor, Boston, Massachusetts 02114 (Address of principal exec |
|
| May 8, 2024 |
Exhibit 99.1 Myomo Reports First Quarter 2024 Financial Results Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 8, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Empl |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, |
|
| May 6, 2024 |
Exhibit 99.1 Myomo Announces First Lump Sum Reimbursements for MyoPros Delivered to Medicare Part B Beneficiaries Under New CMS Fees Claims Remitted for Payment by All Four Billing Regions Orthotics and Prosthetics Providers Beginning to Receive Reimbursement at Published Rates BOSTON (May 6, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company t |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 26, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 25, 2024 |
MYO / Myomo, Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindmyo13ga4apr25.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 4) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) March 31, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| April 25, 2024 |
EX-99.A BD-DIR-RESOL 2 exAmyo14-02-2024.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salagon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Direct |
|
| March 28, 2024 |
Myomo Appoints Heather Getz to its Board of Directors Exhibit 99.1 Myomo Appoints Heather Getz to its Board of Directors BOSTON (March 28, 2024) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit commit |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 8, 2024 |
Exhibit 97.1 Myomo, Inc. COMPENSATION RECOVERY POLICY Adopted as of September 13, 2023 Myomo, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and former Executive Officers |
|
| March 8, 2024 |
Employment Agreement dated December 13, 2023 by and between the Company and Paul R Gudonis Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is between Myomo, Inc. (“Myomo” or the “Company”), a Delaware corporation with offices at 137 Portland St., 4th Floor, Boston, MA 02114, and Paul R. Gudonis, an individual (“Executive”) residing at 56 Masconomo St., Manchester, MA 01944, is made as of the date of the last signature on the signature pages hereto and upon |
|
| March 8, 2024 |
m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 8, 2024 |
Exhibit 21.1 Myomo, Inc. List of Subsidiaries Subsidiary Legal Name Employer ID Number % Owned State/Country Incorporated Myomo Europe GmbH NA 100% Germany |
|
| March 8, 2024 |
Exhibit 10.10 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (the “Amendment”) is made as of February 21, 2024, and amends the Employment Agreement dated April 22, 2021 between Myomo, a Delaware corporation (the “Company”), and Micah Mitchell (the “Executive”) (such Agreement, the “Employment Agreement”). NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, a |
|
| March 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| March 7, 2024 |
Exhibit 99.1 Myomo Reports Fourth Quarter and Full Year 2023 Financial Results Q4 total revenue of $4.8 million, up 18% over the prior year Addition of Medicare Part B patients to backlog results in record 183 MyoPro orders and insurance authorizations received in Q4, up 87% over the prior year Record backlog of 230 patients as of December 31, 2023 Introduces 2024 first quarter and full year guida |
|
| March 1, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2024 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 1, 2024 |
Exhibit 99.1 CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro® Fees for codes L8701 and L8702 are effective as of April 1, 2024 BOSTON (March 1, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that on |
|
| February 22, 2024 |
Amended Employment Agreement by and between Myomo, Inc. and David Henry dated February 21, 2024. Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (the “Amendment”) is made as of February 21, 2024 , and amends the Employment Agreement dated April 22, 2021 between Myomo, a Delaware corporation (the “Company”), and David Henry (the “Executive”) (such Agreement, the “Employment Agreement”). NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, and |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 22, 2024 |
Exhibit 10.2 AMENDED AND RESTATED CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change of Control and Severance Agreement (“Agreement”) is made as of February 21, 2024, and amends, restates and supersedes the Change of Control and Severance Agreement dated September 24th 2020, between Myomo , a Delaware corporation (the “Company”), and Harry Kovelman (the “Executive”). The “T |
|
| February 14, 2024 |
EX-99.A BD-DIR-RESOL 2 exAmyo13ga14-02-2024.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salagon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Di |
|
| February 14, 2024 |
MYO / Myomo, Inc. / PACKER PAUL Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Myomo, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 62857J102 (CUSIP Number) December 31, 2023 (Date of Event which requires Filing of this Statement |
|
| February 14, 2024 |
MYO / Myomo, Inc. / Rosalind Advisors, Inc. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 3) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 14, 2024 |
MYO / Myomo, Inc. / Rosalind Advisors, Inc. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 3) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 14, 2024 |
EX-99.A BD-DIR-RESOL 2 exAmyo13ga14-02-2024.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salagon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Di |
|
| February 7, 2024 |
MYO / Myomo, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) January 16, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| January 17, 2024 |
Myomo Reports Preliminary Fourth Quarter Revenue and Backlog EX-99.1 Exhibit 99.1 Myomo Reports Preliminary Fourth Quarter Revenue and Backlog BOSTON (January 17, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary revenue and operating metrics for the fourth quarter of |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| January 17, 2024 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 PROSPECTUS SUPPLEMENT (to Prospectus dated May 25, 2021) 1,354,218 Shares of Common Stock 224,730 Pre-Funded Warrants 224,730 Shares of Common Stock Underlying Pre-Funded Warrants We are offering 1,354,218 shares of our common stock by this prospectus supplement and the accompanying prospectus. We are also offerin |
|
| January 17, 2024 |
Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market EX-99.2 Exhibit 99.2 Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market BOSTON (January 17, 2024) — Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has entered into securities p |
|
| January 17, 2024 |
EX-4.1 Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK MYOMO, INC. Warrant Shares: Initial Exercise Date: January [•], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at a |
|
| January 17, 2024 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January 16, 2024, between Myomo, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s |
|
| January 17, 2024 |
EX-10.2 Exhibit 10.2 January 16, 2024 Myomo, Inc. 137 Portland St., 4th Floor Boston, Massachusetts 02114 Attn: President and Chief Executive Officer Dear Mr. Gudonis: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Myomo, Inc., a company incorporated under the laws of the State of Delaware (the “Compa |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOM |
|
| November 7, 2023 |
Exhibit 99.1 Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and Authorizations Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients Conference call begins at 4:30 p.m. Eastern time today BOSTON (November 7, 2023) – Myomo, Inc. (NYSE Am |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 6, 2023 |
Exhibit 99.1 CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro® for Review at the Upcoming HCPCS Public Meeting Public Meeting Scheduled for November 29, 2023 BOSTON (November 6, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb |
|
| November 2, 2023 |
Exhibit 99.1 Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit Category Standard Medicare Part B Patients now have access to the MyoPro, which will be reimbursed on a lump sum basis BOSTON (November 2, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering fro |
|
| November 2, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| September 7, 2023 |
MYO / Myomo Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) August 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| August 31, 2023 |
MYO / Myomo Inc / Triple Gate Partners, LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 x831230sc13ga1.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Myomo, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 62857J102 (CUSIP Number) August 24, 2023 (Date of Event which Requires Filing of this Statement) Check the appropria |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| August 28, 2023 |
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK MYOMO, INC. Warrant Shares: Initial Exercise Date: August 29, 2023 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o |
|
| August 28, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 PROSPECTUS SUPPLEMENT (to Prospectus dated May 25, 2021) 5,413,334 Shares of Common Stock 1,920,000 Pre-Funded Warrants 1,920,000 Shares of Common Stock Underlying Pre-Funded Warrants We are offering on a “reasonable best efforts” basis 5,413,334 shares of our common stock at a public offering price of $0.60 per s |
|
| August 28, 2023 |
MYO / Myomo Inc / Rosalind Advisors, Inc. - MYOMO, INC. 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J271 (CUSIP Number) August 25, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule puwsuant to which this Schedule is |
|
| August 28, 2023 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. |
|
| August 28, 2023 |
Exhibit 10.1 August 24, 2023 Myomo, Inc. 137 Portland St., 4th Floor Boston, Massachusetts 02114 Attn: President and Chief Executive Officer Dear Mr. Gudonis: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Myomo, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), tha |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 24, 2023 |
Subject to Completion, dated August 24, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these secu |
|
| August 24, 2023 |
A.G.P. The date of this prospectus supplement is August 24, 2023. 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 25, 2021) This prospectus supplement supplements and amends certain information contained in the prospectus supplement dated August 2, 2022 to the prospectus supplement dated June 25, 2021 to the prospectus dated May 25, 2021 (collectively, the “ATM Prospectus”), relating to the offer |
|
| August 24, 2023 |
Exhibit 99.1 Myomo Receives Medicare Part B Reimbursement for First MyoPro® Claims Appropriate payment amounts received on two MyoPro claims; Additional claims are under review while CMS rulemaking to re-classify the MyoPro to the brace benefit category progresses BOSTON (August 24, 2023) ─ Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers |
|
| August 9, 2023 |
Exhibit 99.1 Myomo Reports Second Quarter 2023 Financial Results Featuring Year Over Year Growth in Revenue and Operating Metrics Q2 revenue of $6.0 million, including license revenue Nearly 1,000 prospective MyoPro® candidates with known payers in the patient pipeline Begins to build Medicare Part B patient pipeline following publication of proposed rule by the Centers for Medicare and Medicaid S |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, IN |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| June 28, 2023 |
EX-99.3 Exhibit 99.3 SECOND AMENDMENT TO THE MYOMO, INC. 2018 STOCK OPTION AND INCENTIVE PLAN This Second Amendment (this “Amendment”) to the Myomo, Inc. 2018 Stock Option and Incentive Plan, as amended (the “Plan”), of Myomo, Inc. (the “Company”) is effective as of the date of approval by the Company’s stockholders (the “Effective Date”). Capitalized terms used herein and not otherwise defined sh |
|
| June 28, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Myomo, Inc. |
|
| June 28, 2023 |
Power of Attorney (see page II-1 of this Registration Statement on Form S-8). S-8 As filed with the U.S. Securities and Exchange Commission on June 28, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MYOMO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-0944526 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Empl |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 10, 2023 |
Exhibit 99.1 Myomo Reports First Quarter 2023 Financial Results Featuring 20% Year Over Year Increase in Product Revenue Implementation of virtual waiting room technology enabled a record 438 patients added to the pipeline, up 54% over Q1 2022 Advertising efficiencies resulted in cost per pipeline add of $1,579, down 50% sequentially Conference call begins at 4:30 p.m. Eastern time today BOSTON (M |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, I |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp |
|
| April 28, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2023 |
DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 10, 2023 |
Exhibit 99.1 Myomo Receives Technology License Fee Payment from China Joint Venture Company Payment of $1.7 million permits the start of activities to manufacture and sell the MyoPro® in China BOSTON (April 10, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 06, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 13, 2023 |
Exhibit 99.1 Myomo Reports Fourth Quarter and Full Year 2022 Financial Results Fourth quarter revenue was $4.0 million, up 2% sequentially 387 patients added to the pipeline in fourth quarter, up 75% compared with Q4 2021 Conference call begins at 10:00 a.m. Eastern time today BOSTON (March 13, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company |
|
| March 13, 2023 |
m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 13, 2023 |
Exhibit 21.1 Myomo, Inc. List of Subsidiaries Subsidiary Legal Name Employer ID Number % Owned State/Country Incorporated Myomo Europe GmbH NA 100% Germany |
|
| March 13, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| February 15, 2023 |
MYO / Myomo Inc / Hewlett Fund LP - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) MYOMO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 62857J201 (CUSIP Number) February 14, 2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule purs |
|
| February 7, 2023 |
MYO / Myomo Inc / Must Asset Management Inc. - SCHEDULE 13G AMENDMENT NO. 2 Passive Investment SCHEDULE 13G AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MYOMO, INC. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 62857J201 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| January 30, 2023 |
Myomo Appoints Yitzchak Jacobovitz to its Board of Directors Exhibit 99.1 Myomo Appoints Yitzchak Jacobovitz to its Board of Directors BOSTON (January 30, 2023) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective Jan |
|
| January 20, 2023 |
MYO / Myomo Inc / PACKER PAUL Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Myomo, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 62857J102 (CUSIP Number) January 12, 2023 (Date of Event which requires Fil |
|
| January 19, 2023 |
MYO / Myomo Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) January 12, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 17, 2023 |
MYO / Myomo Inc / Hewlett Fund LP - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) MYOMO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 62857J201 (CUSIP Number) January 17, 2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule pursuant |
|
| January 13, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| January 13, 2023 |
Exhibit 10.2 January 11, 2023 Myomo, Inc. 137 Portland St., 4th Floor Boston, Massachusetts 02114 Attn: President and Chief Executive Officer Dear Mr. Gudonis: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Myomo, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), th |
|
| January 13, 2023 |
EX-10.1 3 myo-ex101.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January 11, 2023, between Myomo, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to th |
|
| January 13, 2023 |
424B4 1 d364362d424b4.htm 424B4 Table of Contents As Filed Pursuant to Rule 424(b)(4) Registration No. 333-268705 Registration No. 333-269189 PROSPECTUS 13,169,074 Shares of Common Stock 6,830,926 Pre-Funded Warrants 6,830,926 Shares of Common Stock Underlying Pre-Funded Warrants We are offering on a “reasonable best efforts” basis 13,169,074 shares of common stock at a public offering price of $0 |
|
| January 13, 2023 |
EX-4.1 2 myo-ex41.htm EX-4.1 Exhibit 4.1 Pre-Funded WARRANT To purchase Shares of Common Stock MYOMO, INC. Warrant Shares: Initial Exercise Date: January 17, 2023 THIS Pre-Funded WARRANT to Purchase Shares of Common Stock (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions herein |
|
| January 11, 2023 |
As filed with the Securities and Exchange Commission on January 10, 2023. S-1/A Table of Contents As filed with the Securities and Exchange Commission on January 10, 2023. |
|
| January 11, 2023 |
As filed with the Securities and Exchange Commission on January 11, 2023. S-1MEF As filed with the Securities and Exchange Commission on January 11, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MYOMO, INC. (Exact name of Registrant as specified in its charter) Delaware 3842 47-0944526 (State or other jurisdiction of incorporation or organization) (Prim |
|
| January 11, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Myomo, Inc. |
|
| January 10, 2023 |
Form of Securities Purchase Agreement in connection with this offering Exhibit 10.20 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January [], 2023, between Myomo, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fort |
|
| January 10, 2023 |
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK MYOMO, INC. Warrant Shares: Initial Exercise Date: January [ ], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| January 10, 2023 |
Exhibit 99.1 Myomo Announces Initiative to Reduce Cash Burn Undertakes a reduction in force to enhance efficiency in its direct billing channel BOSTON, January 10, 2023 - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced a redu |
|
| January 10, 2023 |
As filed with the Securities and Exchange Commission on January 10, 2023. S-1/A Table of Contents As filed with the Securities and Exchange Commission on January 10, 2023. |
|
| January 4, 2023 |
As filed with the Securities and Exchange Commission on January 4, 2023. S-1/A Table of Contents As filed with the Securities and Exchange Commission on January 4, 2023. |
|
| January 4, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Myomo, Inc. |
|
| January 4, 2023 |
EX-4.1 Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK MYOMO, INC. Warrant Shares: Initial Exercise Date: January [], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an |
|
| January 4, 2023 |
Form of Placement Agent Agreement by and between Myomo, Inc. and A.G.P./Alliance Global Partners EX-1.1 Exhibit 1.1 January [], 2023 Myomo, Inc. 137 Portland St., 4th Floor Boston, Massachusetts 02114 Attn: President and Chief Executive Officer Dear Mr. Gudonis: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Myomo, Inc., a company incorporated under the laws of the State of Delaware (the “Company |
|
| January 4, 2023 |
Form of Securities Purchase Agreement in connection with this offering EX-10.20 Exhibit 10.20 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January [], 2023, between Myomo, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| December 7, 2022 |
As filed with the Securities and Exchange Commission on December 7, 2022. S-1 Table of Contents As filed with the Securities and Exchange Commission on December 7, 2022. |
|
| December 7, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Myomo, Inc. |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 07, 2022 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 25, 2022 |
MYO / Myomo Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) November 18, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOM |
|
| November 10, 2022 |
Exhibit 99.1 Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog Third quarter revenue of $4.0 million, up 8% sequentially 130 authorizations and orders results in a record-high backlog of 184 units Conference call begins at 4:30 p.m. Eastern time today BOSTON (November 10, 2022) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Compan |
|
| October 28, 2022 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 18, 2022 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 3, 2022 |
Exhibit 99.1 Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline Additions Second quarter revenue of $3.7 million up 18% over prior year Cost per pipeline addition cut in half over the last six months Conference call begins at 4:30 p.m. Eastern time today BOSTON (August 3, 2022) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Company?), a wearable medical |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| August 2, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| August 2, 2022 |
424B5 1 d384578d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 SUPPLEMENT TO PROSPECTUS SUPPLEMENT DATED JUNE 25, 2021 (To Prospectus Dated May 25, 2021) Up to $300,000 Common Stock This prospectus supplement, or this supplement, supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our prospectus |
|
| August 2, 2022 |
Up to $5.0 Million of Shares of Common Stock 50,000 Shares of Common Stock 424B5 1 d382569d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 PROSPECTUS SUPPLEMENT (to Prospectus dated May 25, 2021) Up to $5.0 Million of Shares of Common Stock 50,000 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to $5,000,000 in shares of our common stock, par value $0.0001 per share (the “Common Stock |
|
| August 2, 2022 |
EX-1.1 2 d384616dex11.htm EX-1.1 Exhibit 1.1 COMMON STOCK PURCHASE AGREEMENT DATED AS OF AUGUST 2, 2022 BY AND BETWEEN MYOMO, INC. AND KEYSTONE CAPITAL PARTNERS, LLC TABLE OF CONTENTS ARTICLE I PURCHASE AND SALE OF COMMON STOCK 1 Section 1.1 Purchase and Sale of Stock 1 Section 1.2 Commencement Date; Settlement Dates 2 Section 1.3 Current Report; Prospectus Supplement 2 ARTICLE II PURCHASE TERMS 3 |
|
| July 7, 2022 |
Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions EX-99.1 2 myo-ex991.htm EX-99.1 Exhibit 99.1 Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions BOSTON (July 7, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenu |
|
| July 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 07, 2022 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp |
|
| May 18, 2022 |
MYO / Myomo Inc / Must Asset Management Inc. - SCHEDULE 13G AMENDMENT NO. 1 Passive Investment SCHEDULE 13G AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MYOMO, INC. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 62857J201 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp |
|
| May 11, 2022 |
Exhibit 99.1 Myomo Reports First Quarter 2022 Financial Results Revenue of $3.9 million up 66% over prior year, product revenue of $2.9 million up 23% Pipeline of 924 MyoPro candidates up 14% over fourth quarter of 2021 Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 11, 2022) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Company?), a wearable medical robotics company that |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, I |
|
| April 29, 2022 |
DEF 14A 1 d288247ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 4, 2022 |
Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee Exhibit 99.1 Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee BOSTON (April 4, 2022) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Company?), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, provides an update on the status of its joint venture ( |
|
| April 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| March 11, 2022 |
Exhibit 10.29 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. TRADEMARK LICENSE AGREEMENT This TRADEMARK LICENSE AGREEMENT (this ?Trademark License Agreement?) dated as of December 29, 2021, is entered into by and betwe |
|
| March 11, 2022 |
Exhibit 10.27 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDED AND RESTATED EQUITY JOINT VENTURE CONTRACT among ANHUI RYZUR MEDICAL EQUIPMENT MANUFACTURING CO., LTD. (??????????????) WUXI CHINALEAF REHABILITATION |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-3 |
|
| March 11, 2022 |
Exhibit 21.1 Myomo, Inc. List of Subsidiaries Subsidiary Legal Name Employer ID Number % Owned State/Country Incorporated Myomo Europe GmbH NA 100% Germany |
|
| March 11, 2022 |
Exhibit 10.28 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. TECHNOLOGY LICENSE AGREEMENT This TECHNOLOGY LICENSE AGREEMENT (this ?License Agreement?) dated as of December 29, 2021 (the ?Signing Date?), is entered into |
|
| March 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| March 9, 2022 |
Exhibit 99.1 Myomo Reports Fourth Quarter and Full Year 2021 Financial Results Fourth quarter revenue of $4.0 million up 6% over prior year, full year revenue of $13.9 million up 83% over 2020 Fourth quarter gross margin of 77.4% up 400 basis points over prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (March 9, 2022) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Comp |
|
| February 11, 2022 |
MYO / Myomo Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| January 20, 2022 |
MYO / Myomo Inc / Rosalind Advisors, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 20, 2022 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Myomo, Inc. |
|
| January 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| January 10, 2022 |
Myomo Provides Update on MyoPro® Insurance Reimbursement EX-99.1 Exhibit 99.1 Myomo Provides Update on MyoPro® Insurance Reimbursement BOSTON, Mass (January 10, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today provided an update on reimbursement for its MyoPro device by a large privat |
|
| January 5, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOM |
|
| November 10, 2021 |
Exhibit 99.1 Myomo Third Quarter 2021 Financial Results Feature Record Revenue Revenue of $4.4 million up 128% over prior year, up 159% year-to-date Gross margin of 75% up 1,900 basis points over prior year Backlog increased to 177 units Conference call begins at 4:30 p.m. Eastern time today BOSTON, Mass. (November 10, 2021) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Company?), a wearable |
|
| October 15, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| October 15, 2021 |
Exhibit 10.1 October 14, 2021 [Name and address of warrant holder] Re: Exercise Price Reset Offer of Common Stock Purchase Warrants To Whom It May Concern: Myomo, Inc. (the ?Company?) is pleased to offer to you the opportunity to reprice the Exercise Price of all of the Common Stock purchase warrants of the Company (the ?Warrants?) currently held by you (the ?Holder?) and as set forth on your sign |
|
| October 15, 2021 |
Myomo, Inc. Announces Agreements for Exercise of 2020 Investor Warrants Exhibit 99.1 Myomo, Inc. Announces Agreements for Exercise of 2020 Investor Warrants BOSTON, Mass. (October 15, 2021) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Company?), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced it has entered into agreements with certain of its holder |
|
| October 6, 2021 |
MYO / Myomo Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) September 20, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| October 5, 2021 |
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
|
| October 5, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, IN |
|
| August 9, 2021 |
Exhibit 99.1 Myomo Second Quarter 2021 Financial Results Feature Significant Increases in Revenue and Gross Margin, Record Insurance Authorizations and Orders Revenue was $3.1 million, up 262% over prior year Gross margin was 71%, up 2,000 basis points over prior year Insurance authorizations and orders were a record 138 Conference call begins at 4:30 p.m. Eastern time today BOSTON, Mass. (August |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| June 29, 2021 |
Exhibit 10.1 June 27th, 2021 PERSONAL AND CONFIDENTIAL Re: Amendment to Equity Award Dear Jon: This letter agreement (the ?Letter Agreement?) is being entered into by and between you and Myomo, Inc. (the ?Company) in connection with your grant agreements from the Company for time-based and performance-based restricted stock units (?RSU?s?) dated as of June 9, 2021 (collectively, the ?2021 Equity A |
|
| June 25, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 25, 2021) $15,000,000 Common Stock We have entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with A.G.P./Alliance Global Partners, or A.G.P., dated June 25, 2021, relating to the sale of our common stock offered by this prospectus supplement. In ac |
|
| June 25, 2021 |
Sales Agreement, dated June 25, 2021, between the Company and A.G.P./Alliance Global Partners. Exhibit 1.1 MYOMO, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement June 25, 2021 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 Ladies and Gentlemen: Myomo, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with A.G.P./Alliance Global Partners (the ?Agent?) as follows: 1. Issuance and Sale o |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| June 15, 2021 |
Exhibit 3.1 Second Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation Myomo, Inc., a corporation organized and existing under virtue of the provisions of the General Corporation Law of the State of Delaware (the ?DGCL?) does hereby certify as follows: 1) The name of the corporation is Myomo, Inc. (the ?Corporation?). 2) The Eighth Amended and Restated Certific |
|
| June 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp |
|
| June 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp |
|
| June 8, 2021 |
Myomo Provides Update on CMS Discussions Exhibit 99.1 Myomo Provides Update on CMS Discussions BOSTON, Mass. (June 8, 2021) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Company?), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today provided an update regarding its application for a Healthcare Common Procedure Coding System (?HCPCS?) |
|
| May 28, 2021 |
MYO / Myomo Inc / HIRSCHMAN ORIN - AMENDED FORM SC13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 2 Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) May 21, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| May 21, 2021 |
VIA EDGAR May 21, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) May 05, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) |
|
| May 19, 2021 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of VistaGen Therapeutics, Inc. |
|
| May 14, 2021 |
As filed with the Securities and Exchange Commission on May 14, 2021. S-3 1 d465038ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on May 14, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MYOMO, INC. (Exact name of registrant as specified in its charter) Delaware 47-0944526 (State or other jurisdiction of incorpora |
|
| May 11, 2021 |
SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MYOMO, INC. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 62857J201 (CUSIP Number) May 3, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| May 11, 2021 |
EX-99.(A) EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of MYOMO, INC. dated as of May 11, 2021 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 193 |
|
| May 5, 2021 |
EX-99.1 2 d400978dex991.htm EX-99.1 Exhibit 99.1 Myomo Reports First Quarter 2021 Financial Results Revenue of $2.3 million up 132% over prior year Gross margin of 73% up 500 basis points over prior year Q1 cash used in operations decreased 14% to $2.1 million Conference call begins at 4:30 p.m. Eastern time today BOSTON, Mass. (May 5, 2021) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Comp |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, I |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Empl |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 28, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is between Myomo, Inc. (?Myomo? or the ?Company?), a Delaware corporation with offices at 137 Portland St., 4th Floor, Boston, MA 02114, and Paul R. Gudonis, an individual (?Executive?) residing at 56 Masconomo St., Manchester, MA 01944. W I T N E S S E T H: WHEREAS, Myomo desires to continue to employ Executive as its |
|
| April 28, 2021 |
Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 22nd day of April, 2021 (the ?Commencement Date?) between Myomo, a Delaware corporation (the ?Company?), and Micah Mitchell (the ?Executive??). WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the terms contained herein. |
|
| April 28, 2021 |
definitive proxy statement on Schedule 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 28, 2021 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 22nd day of April, 2021, (the ?Commencement Date?) between Myomo, a Delaware corporation (the ?Company?), and David Henry (the ?Executive?). WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to be employed by the Company beginning on the Commencement Date on the term |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| April 16, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 6, 2021 |
Consulting Agreement, dated as of March 31, 2021, between Myomo, Inc. and Jon Naft. Exhibit 10.2 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this ?Agreement?) is between Myomo, Inc. (hereinafter ?Myomo? or ?Customer?), a Delaware corporation, and Jonathan Naft (hereinafter ?Consultant?). This Agreement is made and entered into as of the date of the Transitional Services and Separation Agreement between Myomo and Consultant (the ?Separation Agreement?) and shall, subject to th |
|
| April 6, 2021 |
Exhibit 10.1 March 31, 2021 PERSONAL AND CONFIDENTIAL Jon Naft Re: Transitional Services and Separation Agreement Dear Jon: This letter confirms that the last day of your employment with Myomo, Inc. (the ?Company?) will be March 31, 2021 (the ?Separation Date?) as a result of your resignation without Good Reason as defined under your Employment Agreement between you and the Company dated December |
|
| April 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| March 10, 2021 |
EX-99.1 2 d111974dex991.htm EX-99.1 Exhibit 99.1 Myomo Reports Fourth Quarter and Full Year 2020 Financial Results Record Q4 2020 revenue of $3.8 million up 149% over prior year Full year 2020 revenue of $7.6 million up 98% vs. 2019 Q4 gross margin of 73% up 100 basis points over prior year Q4 cash used in operations of $1.2 million lowest since June 2017 IPO Conference call begins at 4:30 p.m. Ea |
|
| March 10, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-3 |
|
| March 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| March 10, 2021 |
Exhibit 21.1 Myomo, Inc. List of Subsidiaries Subsidiary Legal Name Employer ID Number % Owned State/Country Incorporated Myomo Europe GmbH 100% Germany |
|
| March 10, 2021 |
Exhibit 10.26 SUBLEASE UPSTATEMENT, LLC, a Massachusetts limited liability company ("Sublessor"), with a place of business at 137 Portland Street, Boston, Massachusetts 02114, and MYOMO, INC., a Delaware corporation ("Sublessee"), with a place of business at One Broadway, Cambridge, Massachusetts 02142, make this Sublease as of December 17, 2020 (the ?Effective Date?). Preliminary Statement Subles |
